1. Pathological mechanisms and therapeutic outlooks for arthrofibrosis
   Kayley M. Usher et al, 2019, Bone Research CrossRef
2. Omega-3 derivatives, specialized pro-resolving mediators: Promising therapeutic tools for the treatment of pain in chronic liver disease
   TA Mariqueo et al, 2020, Prostaglandins, Leukotrienes and Essential Fatty Acids CrossRef
3. Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors
   Nan Chiang et al, 2017, Molecular Aspects of Medicine CrossRef
4. Immunomodulatory and biological properties of helminth-derived small molecules: Potential applications in diagnostics and therapeutics
   Karma Yeshi et al, 2022, Frontiers in Parasitology CrossRef
5. N-3 Polyunsaturated Fatty Acids and Their Lipid Mediators as A Potential Immune–Nutritional Intervention: A Molecular and Clinical View in Hepatic Disease and Other Non-Communicable Illnesses
   Francisca Herrera Vielma et al, 2021, Nutrients CrossRef
6. Does promoting resolution instead of inhibiting inflammation represent the new paradigm in treating infections?
   Jesmond Dalli, 2017, Molecular Aspects of Medicine CrossRef
7. Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs
   Melissa Gabbs et al, 2015, Advances in Nutrition CrossRef
8. Resolvin D2 recovers neural injury by suppressing inflammatory mediators expression in lipopolysaccharide-induced Parkinson's disease rat model
   Yuguang Tian et al, 2015, Biochemical and Biophysical Research Communications CrossRef
9. Pro-Resolving Lipid Mediator Resolvin E1 Mitigates the Progress of Diethylnitrosamine-Induced Liver Fibrosis in Sprague-Dawley Rats by Attenuating Fibrogenesis and Restricting Proliferation
   Maria José Rodríguez et al, 2020, International Journal of Molecular Sciences CrossRef
10. Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances
    Giovanni Musso et al, 2023, Progress in Lipid Research CrossRef
11. Resolvin D1 and E1 alleviate the progress of hepatitis toward liver cancer in long-term concanavalin A-induced mice through inhibition of NF-κB activity
    HAOYU KUANG et al, 2016, Oncology Reports CrossRef
12. Chemokine-Like Receptor 1 mRNA Weakly Correlates with Non-Alcoholic Steatohepatitis Score in Male but Not Female Individuals
    Maximilian Neumann et al, 2016, International Journal of Molecular Sciences CrossRef
13. Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis
    Giovanni Musso et al, 2018, Gastroenterology CrossRef
14. The Role of Endogenous Eicosapentaenoic Acid and Docosahexaenoic Acid-Derived Resolvins in Systemic Sclerosis
    Aslıhan Avanoǧlu Güler et al, 2020, Frontiers in Immunology CrossRef
15. Omega-3 Lipid Mediators: Modulation of the M1/M2 Macrophage Phenotype and Its Protective Role in Chronic Liver Diseases
    Luis Alberto Videla et al, 2023, International Journal of Molecular Sciences CrossRef
16. Protective effects of extracts from Pomegranate peels and seeds on liver fibrosis induced by carbon tetrachloride in rats
    Xiang-lan Wei et al, 2015, BMC Complementary and Alternative Medicine CrossRef
17. Specialized pro-resolving mediators in renal fibrosis
    Eoin P. Brennan et al, 2017, Molecular Aspects of Medicine CrossRef
18. Specialized Pro-Resolving Mediators Derived from N-3 Polyunsaturated Fatty Acids: Role in Metabolic Syndrome and Related Complications
    Laurent Dubé et al, 2022, Antioxidants & Redox Signaling CrossRef
19. Treating inflammation and infection in the 21st century: new hints from decoding resolution mediators and mechanisms
    Charles N. Serhan, 2017, The FASEB Journal CrossRef
20. Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution
    Giovanni Musso et al, 2018, Trends in Pharmacological Sciences CrossRef
21. Bioactive signalling lipids as drivers of chronic liver diseases
    Eleanna Kaffe et al, 2024, Journal of Hepatology CrossRef